Objective: To determine if the CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age !75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, sex category) predicts thromboembolism and death in patients without atrial fibrillation in a population with implantable cardiac monitoring devices. Patients and Methods: A retrospective review utilizing the Rochester Epidemiology Project research infrastructure was conducted to evaluate the CHA 2 DS 2 -VASc tool as a predictor of mortality and ischemic stroke, transient ischemic attack, or systemic embolism in patients without atrial fibrillation. An implantable device was required in the inclusion criteria to discern the absence of atrial fibrillation. The study period was January 1, 2004, through March 7, 2016. Results: The study population (N¼1606) had a mean (SD) age of 69.8 (12.6) years and median followup of 4.8 years (range, 0-12 years; quartile 1, 2.6 years and quartile 3, 8.1 years). The number of thromboembolic and mortality events stratified by CHA 2 DS 2 -VASc score groupings of 0 to 2 (399 patients), 3 to 5 (756 patients), and 6 to 9 (451 patients) were 12 (3.0%), 109 (14.4%), and 123 (27.3%) and 22 (5.5%), 205 (27.1%), and 214 (47.4%), respectively. The CHA 2 DS 2 -VASc score predicted thromboembolism and death. The hazard ratios (HRs) for thromboembolic events for CHA 2 DS 2 -VASc scores 3 to 5 and 6 to 9 were 4.84 (95% CI, 2.66-8.80) and 10.53 (95% CI, 5.77-19.21) (reference group, scores 0-2). The HRs for death for the corresponding score categories were 4.45 (95% CI, 2.86-6.91) and 8.18 (95% CI,). The CHA 2 DS 2 -VASc score also predicted development of atrial fibrillation, for which the HRs for scores 3 to 5 and 6 to 9 were 1.51 (95% CI, 1.13-2.00) and 2.17 (95% CI, 1.60-2.95). Conclusion: The CHA 2 DS 2 -VASc tool predicts thromboembolic events and overall mortality in patients without atrial fibrillation who have implantable devices.
T he CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age !75 years, diabetes mellitus, stroke or transient ischemic attack [TIA] , vascular disease, age 65-74 years, sex category) score is a validated tool to predict the risk of stroke and systemic emboli in patients with nonvalvular atrial fibrillation. [1] [2] [3] [4] The CHA 2 DS 2 -VASc score is recommended for assessment of systemic emboli risk in patients with nonvalvular atrial fibrillation, and oral anticoagulation is recommended for those patients with a score of 2 or greater. 5 Treatment with an oral anticoagulant or aspirin in this population may be considered for a CHA 2 DS 2 -VASc score of 1. 5 Given these 2014 American Heart Association/ American College of Cardiology/Heart Rhythm Society guidelines, the use of CHA 2 DS 2 -VASc in determining the need for anticoagulation in patients with nonvalvular atrial fibrillation has become standard practice.
The components of the CHA 2 DS 2 -VASc score have been reported separately to represent significant risk factors for embolism, with certain elements such as prior stroke or TIA and age carrying particular weight. [6] [7] [8] [9] Although the thromboembolic predictive value of CHA 2 DS 2 -VASc score in populations without atrial fibrillation is less established, the individual components are associated with an increased incidence of systemic emboli and mortality, both in patients with atrial fibrillation and those with prior stroke without atrial fibrillation.
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The aim of the present study was to determine the association between the CHA 2 DS 2 -VASc score and mortality, ischemic stroke, TIA, or systemic embolism in patients without atrial fibrillation as assessed by a pacemaker, implantable cardioverter-defibrillator (ICD), or loop recorder in the Olmsted County, Minnesota, population. The development of atrial fibrillation and the effect of anticoagulation and prior renal impairment were also of interest. Renal impairment was evaluated because research has found that patients with renal dysfunction and atrial fibrillation represent a group at high risk for systemic thromboembolic events; however, studies have reported conflicting results about whether kidney function should be incorporated into risk stratification. [15] [16] [17] 
PATIENTS AND METHODS
We conducted a retrospective review utilizing the resources of the Rochester Epidemiology Project (REP), which links and indexes the medical records of Olmsted County, Minnesota, residents. 18 The study was approved by the Olmsted Medical Center and Mayo Clinic institutional review boards. This study was considered minimal risk by the institutional review boards; therefore, the requirement for informed consent was waived. The records of any patient who did not provide authorization for their medical records to be used for research, as per Minnesota statute (Statute 144.335), were not included.
We identified all patients who had an implantable pacemaker, defibrillator, or loop recorder placed between January 1, 2004, and December 31, 2013, with the index date (time zero) defined as the date of device implantation. The presence of any atrial fibrillation was assessed by implanted cardiac devices, which allow continuous and accurate monitoring of heart rhythms such as atrial fibrillation. 19 The presence of an implanted electronic cardiac device was an inclusion criterion for the study in order to provide objective evidence that the population evaluated did not have clinically important atrial fibrillation burden. Follow-up was defined as the time to first thromboembolic event, death, or the end of the study period (which was the time of data collection, March 7, 2016) . Patients included were older than 50 years and had no diagnosis of atrial fibrillation before the index date. Figure 1 describes the process for generating the cohort.
A total of 3033 patients were identified as having a qualifying implantable device, and 1427 of these patients were excluded because they had an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis of atrial fibrillation before device implantation. Thus, 1606 patients met inclusion criteria. The ICD-9 diagnostic codes were used to identify the CHA 2 DS 2 -VASc variables at the index date and as they developed over time. The International Classification of Diseases is the official system of assigning codes to diagnoses associated with hospital utilization in the United States and is based on the World Health Organization's International Classification of Diseases.
The ICD-9 diagnostic code sets were developed for the CHA 2 DS 2 -VASc components of congestive heart failure, hypertension, diabetes mellitus, ischemic stroke, and TIA. The ICD-9 codes for coronary artery disease, angina, ischemic heart disease, and peripheral vascular disease were utilized to comprise a code set for vascular disease. Renal impairment and the development of atrial fibrillation were also identified using ICD-9 diagnostic codes. Renal impairment was defined as end-stage renal disease, dialysis, or stage 3 or higher chronic kidney disease. Data on prescriptions for oral anticoagulation (warfarin, dabigatran, apixaban, or rivaroxaban) were also obtained. Outpatient prescriptions were obtained from Mayo Clinic and Olmsted Medical Center, converted into RxNorm codes, and subsequently grouped using the National Drug-File Reference Terminology. 20 The primary outcome was defined as the first thromboembolic event including ischemic stroke, TIA, or systemic emboli that was diagnosed using ICD-9 codes after the index date through March 7, 2016 . A random sample of thromboembolic events in the identified population was verified by manual medical record review, and 100% of these events were found to represent true outcomes. Survival was a secondary outcome, identified from inpatient and outpatient medical records, death certificates from the state of Minnesota, and obituaries and notices of death in the local newspapers.
The baseline CHA 2 DS 2 -VASc score including its individual components, renal impairment, and oral anticoagulation use were recorded for each patient. Baseline characteristics and baseline CHA 2 DS 2 -VASc scores were taken at the index date (corresponding to date of cardiac monitoring device implantation or time zero). The CHA 2 DS 2 -VASc score components and oral anticoagulation use were also recorded as time-dependent variables after the index date. 21 Patients were classified into subgroups according to the following baseline CHA 2 DS 2 -VASc scores: 0 to 2, 3 to 5, and 6 to 9. Events stratified by CHA 2 DS 2 -VASc score were evaluated by Kaplan-Meier curves and were compared using a log-rank test. Multivariate modeling of thromboembolic events and survival was performed with use of Cox proportional hazards models. P<.05 was considered statistically significant. Hazard ratios (HRs) and corresponding 95% CIs were generated for CHA 2 DS 2 -VASc scores 3 to 5 and 6 to 9, with the CHA 2 DS 2 -VASc score 0 to 2 used as the reference group. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute).
RESULTS
The baseline characteristics of the cohort are presented in 
The Rochester Epidemiology Project database was searched to identify the study cohort. Descriptive statistics of the study sample stratified by initial use of oral anticoagulation are also shown. a Analysis was performed on the entire population meeting inclusion criteria (N¼1606). Listed subgroups are for descriptive purposes.
b Of the 1606 patients included in the study cohort, 228 (14.2%) started oral anticoagulation after device implantation. Outcome counts reported in the final row were seen after a median follow-up of 4.8 years and reflect cumulative counts at the end of the study period.
at the date of device implantation is presented in Table 2 .
The incidence of thromboembolic events and death by CHA 2 DS 2 -VASc score is shown in Figure 2 , A and B. The number of thromboembolic events and overall mortality events stratified by CHA 2 DS 2 -VASc score groupings of 0 to 2 (399 patients), 3 to 5 (756 patients), and 6 to 9 (451 patients) were 12 (3.0%), 109 (14.4%), and 123 (27.3%) and 22 (5.5%), 205 (27.1%), and 214 (47.4%), respectively. Cumulative mortality at 6 months and at 5 years for CHA 2 DS 2 -VASc scores 0 to 2, 3 to 5, and 6 to 9 was 1.5% (95% CI, 0.3%-2.7%), 2.5% (95% CI, 1.4%-3.6%), and 5.8% (95% CI, 3.6%-7.9%) and 4.4% (95% CI, 2.2%-6.6%), 19.3% (95% CI, 16.1%-22.4%), and 34.3% (95% CI, 29.3%-38.1%), respectively. Cumulative incidence of thromboembolism at 6 months and at 5 years for CHA 2 DS 2 -VASc scores 0 to 2, 3 to 5, and 6 to 9 was 0.5% (95% CI, 0.0%-1.2%), 3.9% (95% CI, 2.5%-5.3%), and 8.2% (95% CI, 5.6%-10.8%) and 1.9% (95% CI, 0.5%-3.3%), 14.1% (95% CI, 11.2%-17.0%), and 29.4% (95% CI, 24.4%-34.2%), respectively. The incidence of thromboembolic events in the entire population (1606 patients) at 3 months and 5 years was 41 (2.6%) and 200 (12.5%), respectively. Development of atrial fibrillation by CHA 2 DS 2 -VASc score grouping is shown in Figure 2 , C. The number of patients who had development of atrial fibrillation stratified by CHA 2 DS 2 -VASc score groupings of 0 to 2, 3 to 5, and 6 to 9 was 65, 185, and 144, respectively (394 of the 1606 patients [24.5%]). The cumulative incidence of atrial fibrillation at 6 months and at 5 years for CHA 2 DS 2 -VASc scores 0 to 2, 3 Table 1 , available online at http://www.mayoclinicproceedings.org).
The HRs for development of atrial fibrillation for CHA 2 DS 2 -VASc scores 3 to 5 and 6 to 9 were 1.51 (95% CI, 1.13-2.00) and 2.17 (95% CI, 1.60-2.95), respectively. Patients in whom atrial fibrillation developed had an HR for death of 2.35 (95% CI, 1.86-2.97) and an HR for thromboembolic events of 1.99 (95% CI, 1.39-2.84). Anticoagulation after the index date had an HR for death of 0.92 that was not significant (95% CI, 0.69-1.22; P¼.55). Anticoagulation after the index date had an HR for thromboembolic events of 0.77, which also was not significant (95% CI, 0.47-1.28; P¼.32). The subpopulation who began oral anticoagulation after the index date was small (n¼228). The HR for death for those with renal impairment at the index date was 1.92 (95% CI, 1.53-2.42), and the HR for thromboembolic events was not significant (HR, 1.25; 95% CI, 0.90-1.75; P¼.19).
The HRs for outcomes of interest based on development of CHA 2 DS 2 -VASc components after the index date are presented in Table 4 . Incident thromboembolism had the largest HR for mortality (HR, 2.35; 95% CI, 1.78-3.10). Incident heart failure had an HR for 
DISCUSSION
The CHA 2 DS 2 -VASc score is a well-validated tool for predicting thromboembolism and initiating anticoagulation in populations with atrial fibrillation. The CHA 2 DS 2 -VASc score has been evaluated by several studies in patients without atrial fibrillation who had a prior stroke. A 5-year prospective study found that the CHA 2 DS 2 -VASc score predicts long-term stroke outcomes in patients with a first ischemic stroke but without atrial fibrillation. 14 A study of patients with ischemic stroke found that the prestroke CHA 2 DS 2 -VASc score has high sensitivity for estimating 3-month stroke outcomes in both patients with and without atrial fibrillation. 22 In a population of patients with stroke and heart failure, early and late stroke outcome was not associated with the presence of atrial fibrillation.
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Subclinical atrial fibrillation may contribute to the observation that the CHA 2 DS 2 -VASc score was predictive of thromboembolism in certain patient groups without atrial fibrillation. The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) found that device-detected atrial tachyarrhythmias lasting longer than 6 minutes were associated with an increased risk of systemic embolism. 23 The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk study and subgroup analysis of the Mode Selection Trial also reported increased thromboembolic events with device-detected atrial tachyarrhythmias. 24, 25 Further analysis of the ASSERT data indicated that there was not a strong temporal relationship between the tachyarrhythmia and the thromboembolic event (only 8% of patients had subclinical atrial fibrillation detected within 30 days before the thromboembolic event). 26 Research indicates that atrial fibrillation is associated with stroke risk regardless of whether or not it is sustained. 27 The burden of atrial fibrillation detected by implanted electronic cardiac devices predicts ischemic stroke. There is also an apparent correlation between atrial fibrosis and the persistence and burden of atrial fibrillation. 27 Atrial fibrosis and associated inflammation may contribute to both the pathophysiology of atrial fibrillation and thromboembolism and perhaps explain why atrial fibrillation does not necessarily precede embolic events. [29] [30] [31] [32] In a study of patients with paroxysmal atrial fibrillation who underwent ablation, latent high coagulation activity was observed in the left atrium. 30 This activity was significantly lower in patients taking warfarin. Ablation does not halt fibrosis progression, which suggests that inflammation is not solely the result of atrial fibrillation. 33 A prospective study found that the CHADS 2 score (congestive heart failure, hypertension, age !75 years, diabetes mellitus, and stroke) correlated with higher left atrial fibrosis in patients with atrial fibrillation and that atrial fibrosis independently predicted cerebrovascular events and significantly increased the predictive performance of the score. 34 Atrial inflammation may possibly be assessed by risk factors encompassed within the CHA 2 DS 2 -VASc score. An association has been noted between inflammatory parameters and CHA 2 DS 2 -VASc score in patients with nonvalvular atrial fibrillation.
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In our retrospective study, the CHA 2 DS 2 -VASc score predicted thromboembolic events in those without atrial fibrillation as evaluated by implantable electronic cardiac devices. This finding is consistent with those from studies of patients with prior stroke. This is the first study, to our knowledge, to evaluate the CHA 2 DS 2 -VASc score in patients without atrial fibrillation that is not limited to patients with a history of stroke or heart failure. The CHA 2 DS 2 -VASc score also predicted all-cause mortality in patients without atrial fibrillation, which is expected given the increased incidence of thromboembolic events and the increased comorbidities inherent in the score calculation. Our results align with those of the few studies that have evaluated the relationship between CHA 2 DS 2 -VASc score and death irrespective of the presence of atrial fibrillation. 14, 36 Incident thromboembolism and heart failure were most associated with mortality of the evaluated variables that developed after the index date. Incident hypertension was associated with thromboembolic events. The few studies evaluating the utility of the CHA 2 DS 2 -VASc score in populations without atrial fibrillation have not commented specifically on the relationship between incident CHA 2 DS 2 -VASc components and thromboembolic and mortality outcomes. In a retrospective study evaluating the CHADS 2 score, baseline age followed by heart failure and then previous stroke were the components that had the highest impact on all-cause mortality in patients with and without documented atrial fibrillation.
11 A study in patients with congestive heart failure but not atrial fibrillation found that all baseline CHA 2 DS 2 -VASc components were independently associated with ischemic stroke. The incidence of thromboembolism and death was substantial in our study, particularly with CHA 2 DS 2 -VASc scores greater than 2. The percentages of patients experiencing a thromboembolic event during the study period for CHA 2 DS 2 -VASc scores 0 to 2, 3 to 5, and 6 to 9 were 3.0%, 14.4%, and 27.3%. However, the study period was more than 10 years, perhaps partially accounting for the high incidence. The incidence of thromboembolic events in the overall population by 3 months was 2.6%. This incidence is less than the ASSERT study's thromboembolism incidence at 3 months in the subclinical atrial tachyarrhythmia group (4.2%) and higher than that in the nonarrhythmia group (1.7%). 23 In a congestive heart failure population, the incidence of thromboembolism at 5 years was 16.5% in those without atrial fibrillation and 11.9% in those with atrial fibrillation, 36 compared to 12.4% at 5 years in our study. The death incidence during the study period for CHA 2 DS 2 -VASc scores 0 to 2, 3 to 5, and 6 to 9 was 5.5%, 27.1%, and 47.4%. The high baseline prevalence and high incident CHA 2 DS 2 -VASc variables indicate a population with high morbidity.
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Our study results also reveal that the CHA 2 DS 2 -VASc score predicted new-onset atrial fibrillation in the population. This finding indicates that the components of the CHA 2 DS 2 -VASc score may impact risk for atrial fibrillation and associated thromboembolic events. Of evaluated variables, only incident heart failure and diabetes mellitus predicted the development of atrial fibrillation after the index date. A large prospective study also found that CHA 2 DS 2 -VASc score predicted atrial fibrillation, and all CHA 2 DS 2 -VASc components were predictive, particularly age and heart failure. 37 A relatively large number of patients experienced atrial fibrillation after device implantation in our study. As described, CHA 2 DS 2 -VASc score has been found to correlate with atrial inflammation, and therefore, it possibly underlies the association between a higher CHA 2 DS 2 -VASc score and the development of both atrial fibrillation and thromboembolism. Furthermore, there may have been an increased prevalence of undiagnosed paroxysmal atrial fibrillation preceding device implantation in study patients with high CHA 2 DS 2 -VASc scores. A lag could exist between subclinical atrial arrhythmias and clinical detection. There also may be a higher prevalence of subclinical atrial tachyarrhythmias in patients with implantable devices and highrisk groups. The ASSERT trial also found that atrial tachyarrhythmias occurred in a large percentage (10% within 3 months of device implantation) of the population, composed of patients 65 years of age or older without clinical atrial fibrillation. 23 It may be of value for clinicians to be increasingly vigilant in evaluating for the presence of atrial fibrillation in patients with high CHA 2 DS 2 -VASc scores in order to facilitate anticoagulation before thromboembolism develops.
Although the present study did not aim to evaluate anticoagulation as an intervention, oral anticoagulation after the index date resulted in HRs of 0.92 (P¼.55) and 0.77 (P¼.32) for death and thromboembolism, respectively, although these HRs were not significant. This lack of significance is likely related to the small sample size of the subpopulation. Intervention studies evaluating adverse bleeding events would be of interest, and specific score cut points for anticoagulation initiation would be better established by a larger cohort.
A limitation of our study is that it is a retrospective review, and a larger, prospective study would yield higher evidence data. A portion of the population received oral anticoagulation (8.5% were taking anticoagulatants at the index date and 14.2% took anticoagulatants during the study period). Anticoagulation may affect the incidence of thromboembolic events and may have lessened the risk observed with increasing CHA 2 DS 2 -VASc score. Conversely, it also may indicate unmeasured confounders predisposing to outcome events. Antiplatelet agents were not included as part of the analysis. Just under 25% of patients had development of atrial fibrillation, but atrial fibrillation was modeled as a time-dependent covariate in the statistical model to adjust the results. Nevertheless, CHA 2 DS 2 -VASc score remained predictive. There may be associated confounding variables that relate more strongly to atrial fibrillation, such as atrial inflammation. A propensity analysis for the atrial fibrillation subpopulation was not completed. Diagnosis codes were used to define atrial fibrillation, end points, and measured variables. These factors were not verified manually, including atrial fibrillation, which was not further evaluated through device interrogation reports.
CONCLUSION
The present retrospective review utilizing the REP medical records linkage system revealed that the CHA 2 DS 2 -VASc score was an independent predictor of thromboembolic events and mortality in patients with a monitoring device and no atrial fibrillation. Increased incidence of atrial fibrillation was predicted by the CHA 2 DS 2 -VASc score and may further support consideration of anticoagulation in this population.
Anticoagulation is associated with major bleeding risks, and thus the risk of embolization should exceed this risk of bleeding for anticoagulation to provide net benefit. This study may help to lay the foundation for the use of anticoagulation in patients without atrial fibrillation who have a substantial risk of thromboembolic events as assessed by the CHA 2 DS 2 -VASc score. Larger prospective studies that consider bleeding risk are warranted to further investigate whether the CHA 2 DS 2 -VASc score can be effectively utilized to risk stratify patients without atrial fibrillation for anticoagulation.
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